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A 43 year-old male was referred for pharma-
cological stress testing in 2010 in the setting of in-
creasing dyspnea on exertion and atypical chest
pain. He had been diagnosed with hypertrophic car-
diomyopathy following a ventricular fibrillation ar-
rest in 2004. At that time, he underwent a negative
evaluation for coronary atherosclerosis and intra-
cardiac defibrillator implantation, and had done well
since. Upon regadenoson injection (0.4 mg over 10 s)
he became tachycardic, diaphoretic, and complained
of severe chest tightness. His ECG showed exag-
geration of baseline abnormalities, non-specific for
ischemia (Figs. 1, 2). He was given aminophylline
(150 mg intravenous) with resolution of his symp-
toms. Myocardial imaging revealed a moderate to
large-sized reversible defect involving the antero-
septal, anterior, and inferolateral walls, as well as
stress-associated left ventricular dilation (Fig. 3).
Subsequent coronary angiography was negative for
significant coronary artery disease or anatomical
coronary anomalies (Fig. 4).
Adenosine and its analogs provoke coronary va-
sodilation via activation of A2A type adenosine recep-
tors, and are useful as pharmacological stress agents
by exploiting flow-reserve differences between nor-
mal and atherosclerotic coronary artery segments [1].
However, coronary vasospasm is a well-known occur-
rence of adenosine administration, and milder side
effects are frequently encountered, likely related to
the activation of non-A2A type receptors [2].
Figure 1. Electrocardiogram demonstrating sinus rhythm with baseline ST-T wave abnormalities.
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Figure 2. Electrocardiogram at 17 s of recovery after regadenoson injection. Non-specific for ischemia given baseline
abnormalities.
Figure 3. Myocardial perfusion images obtained after regadenoson injection demonstrating perfusion defects in
a multi-vessel distribution.
Regadenoson is a newer pharmacologic stress
agent with a ten-fold higher selectivity for the A2A
adenosine receptor. With comparable efficacy in the
detection of ischemia, regadenoson is also associated
with fewer side effects than adenosine [3]. To the
best of our knowledge, there have been no pre-
vious reports of regadenoson-associated coronary
vasospasm.
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In this case, the occurrence of clinical angina
with a temporary perfusion defect, in the absence
of coronary atherosclerosis, is consistent with acute
coronary vasospasm. Regadenoson-mediated ade-
nosine receptor activation as the provocateur of
coronary vasospasm in this instance is substantiat-
ed by the temporal relationship between the perfu-
sion defect at the onset and subsequent pharmaco-
logic reversal of adenosine receptor activation.
The mechanism of coronary vasospasm upon
adenosine receptor activation remains poorly under-
stood. Proposed mechanisms include genetic differ-
ences in proteins downstream of the clinical target
(A2A receptor), such as the vascular KATP channel [4],
or activation of non-A2A adenosine receptors [5]. The
present case supports the notion that this pheno-
menon is probably a consequence of A2A adenosine
receptor, and not off-target receptor, activation.
As we gain more clinical experience with ade-
nosine analogs, the comparative incidence of vaso-
spasm between agents with different selectivities
for the A2A receptor may yield additional mechanis-
tic insights.
Figure 4. Coronary angiography depicting the absence of atherosclerosis; RCA — right coronary artery; LAD — left
anterior descending artery; LCx — left circumflex artery.
For the present time, we suggest that the prac-
titioner be aware of this possible complication, and
be prepared to provide receptor antagonism should
signs of myocardial ischemia develop upon regade-
noson administration.
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